X4 Pharmaceuticals, Inc. (XFOR) on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for mavorixafor for the treatment of WHIM syndrome, a rare congenital immunodeficiency disorder.
A decision from the European Commission is anticipated in the second quarter of 2026.
The opinion was supported by positive results from a pivotal Phase 3 trial evaluating the efficacy and safety of XOLREMDI in patients aged 12 years and older with WHIM syndrome.
In January 2025, X4 had entered into a licensing and supply agreement with Norgine under which Norgine will commercialize mavorixafor in Europe, Australia and New Zealand following regulatory approvals. X4 is eligible to receive up to $226 million tied to regulatory and commercial milestones, along with escalating double-digit royalties of up to the mid-twenties percentage on future net sales in the licensed territories.
On Thursday, X4 Pharma shares closed at $3.25, down 5.52%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.